June 1, 2018, 4:09pm CDT: Oral Presentation of 2X-121 Abstract at ASCO 2018

Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2 and tankyrase 1/2 inhibitor, as monotherapy in patients with advanced solid tumors.

Abstract Title:            First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP®) mRNA biomarker.

Abstract No.:              2505

Date:                            June 1, 2018

Time:                           4:09pm CDT

Location:                    S406

Access abstract online.